Meeting
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
Authors
Lisanne P. Zijlker
Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
Lisanne P. Zijlker , Winan J. van Houdt , Emma H.A. Stahlie , Viola Franke , Maartje W. Rohaan , Antonios Delatzakis , Charlotte Zuur , Willem M.C. Klop , Bart A. van de Wiel , Anke Kuijpers , Elianne de Boer , Johannes V. van Thienen , John B. A. G. Haanen , Alexander Christopher Jonathan Van Akkooi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04330430
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9546)
DOI
10.1200/JCO.2023.41.16_suppl.9546
Abstract #
9546
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
First Author: Maartje W. Rohaan
Poster
2023 ASCO Annual Meeting
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
First Author: Minke W. Lucas
Poster
2023 ASCO Annual Meeting
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
First Author: Lili Mao
Poster
2023 ASCO Annual Meeting
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
First Author: Faisal Fa'ak